Wedbush Maintains Outperform on Inozyme Pharma, Announces $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst David Nierengarten maintains an Outperform rating on Inozyme Pharma (NASDAQ:INZY) and announces a $15 price target.
September 08, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst maintains Outperform rating on Inozyme Pharma and sets a $15 price target.
The Outperform rating maintained by Wedbush indicates a positive outlook for Inozyme Pharma. The $15 price target suggests that the analyst expects the stock price to rise in the short term. This could potentially lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100